

PRESS CLIPPING SHEET

PUBLICATION:	Business Today
DATE:	April 2019
COUNTRY:	Egypt
CIRCULATION:	10,000
TITLE :	Novartis launches first summit to probe cancer and hematological oncology treatment in Egypt
PAGE:	184
ARTICLE TYPE:	Agency-Generated News
REPORTER:	Staff Report
AVE:	1,500

Novartis launches first summit to probe cancer and hematological oncology treatment in Egypt

Novartis Pharma held the first conference focused on hematological oncology and blood disease treatments in Egypt, titled "Reimagining Cancer". The conference is part of the company's ongoing commitment towards cancer patients and their access to the best and most advanced medication available.

Fourteen universities and institutes and more than 350 guests, as well as 70 local and two international speakers were invited to in-depth discussions on cancer and hematological disorders including thalassemia, chronic leukemia, breast cancer and neuroendocrine tumors and their treatments.

The conference also addressed specific hematological disorders prevalent in Egypt such as thalassemia, a severe form of anemia that is most often of a hereditary origin. In fact, 9% of Egyptians are carriers of the gene that is at the root of the disease, which is one of the highest rates in the world.

